Martin Dawson, MD
Cardiovascular Disease · Mullica Hill, NJNPI 1609815836
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,017 of the $10,067 with a category attached, or 79.6%. It is spread thinly across 35 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 493 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kiniksa Pharmaceuticals, Ltd.$2K
- Novartis$899
- E.r. Squibb & Sons, L.L.C.$799
- AstraZeneca$754
- Johnson & Johnson$606
- Amgen$588
- plus $4K from 29 others
Across 4 payments — averaging $13,199 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$53K
What the payments were for
- Consulting fees$2,00020%
- Food & beverage$8,01780%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | 11 | $2,144 |
| Novartis | 58 | $899 |
| E.r. Squibb & Sons, L.L.C. | 47 | $799 |
| AstraZeneca | 36 | $754 |
| Johnson & Johnson | 61 | $606 |
| Amgen | 39 | $588 |
| Novo Nordisk | 38 | $571 |
| Boehringer Ingelheim | 27 | $499 |
| Esperion Therapeutics, Inc. | 19 | $350 |
| W. L. Gore & Associates, Inc. | 16 | $289 |
| Pfizer | 18 | $269 |
| Merck | 18 | $268 |
| Medtronic(2 entities) | 11 | $262 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $258 |
| Amarin Pharma, Inc. | 15 | $176 |
| Penumbra, Inc. | 1 | $167 |
| Philips North America LLC | 15 | $162 |
| Alnylam Pharmaceuticals Inc. | 9 | $151 |
| Bayer | 7 | $147 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $115 |
| Irhythm Technologies, Inc. | 6 | $99 |
| Abiomed | 3 | $87 |
| Boston Scientific | 3 | $79 |
| Impulse Dynamics (USA) Inc. | 1 | $57 |
| Cvrx, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Kestra Medical Technology Services, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Lilly USA, LLC | 1 | $19 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Cardinal Health 200 LLC | 1 | $18 |
| Abbott | 1 | $17 |
| Chiesi USA, Inc. | 1 | $17 |
| Edwards Lifesciences | 1 | $13 |
| Cashflow Solutions, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,067 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $212,929 |
| XareltoRivaroxaban | 77 | $72,469 |
| FarxigaDapagliflozin Propanediol | 31 | $46,349 |
| JardianceEmpagliflozin | 21 | $31,047 |
| OzempicSemaglutide | 14 | $18,421 |
| Metoprolol Succinate | 337 | $4,858 |
| Atorvastatin Calcium | 341 | $4,563 |
| Valsartan | 64 | $2,873 |
| Ezetimibe | 88 | $2,595 |
| Propafenone Hcl | 41 | $2,466 |
| Lisinopril | 208 | $1,877 |
| Dofetilide | 20 | $1,850 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 44 | $1,590 |
| Furosemide | 241 | $1,445 |
| Amlodipine Besylate | 193 | $1,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $269 | $212,929184 claims |
| Johnson & JohnsonXarelto | $606 | $72,46977 claims |
| AstraZenecaFarxiga | $754 | $46,34931 claims |
| Boehringer IngelheimJardiance | $499 | $31,04721 claims |
| Novo NordiskOzempic | $571 | $18,42114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Mullica Hill
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.